Cellular Immunotherapy for Sarcomas is under clinical development by Italian Sarcoma Group and currently in Phase I for Sarcomas. According to GlobalData, Phase I drugs for Sarcomas have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy for Sarcomas’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cellular Immunotherapy for Sarcomas overview
Cellular immunotherapy is under investigation for the treatment of relapsed and non-resectable sarcomas. The drug candidate comprises of autologous cytokine-induced killer cells.
See Also:
Italian Sarcoma Group overview
Italian Sarcoma Group (ISG) is a healthcare service provider that offers therapies. The center provides therapeutic protocols and diagnosis on sarcomas. It also promotes the preparation and implementation of protocols therapeutic and research on sarcomas. ISG mainly organizes conferences, seminars and other initiatives to promote scientific researches. The center also provides courses, educational activities, internet, and in scientific journals to provide a common treatment. Its therapies are used in treatment of orthopaedic surgeries, oncology, pathology, general surgeries, radiotherapy and basic research and radiology, among others. The center also organizes conferences, seminars and other initiatives to promote scientific research into sarcomas. ISG is headquartered in Bologna, Italy.
For a complete picture of Cellular Immunotherapy for Sarcomas’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
